Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market size evolved in recent years?

In recent times, the market size for uveitis treatment has seen a significant increase. It is projected to expand from a worth of $1.43 billion in 2024 to $1.54 billion in 2025, sustaining an annual growth rate of 8.1%. The historic growth can be credited to several factors such as a rise in autoimmune diseases, growing geriatric demographics, increasing cases of uveitis, heightened awareness about the need for early detection and treatment among healthcare professionals, and a surge in the occurrence of infectious diseases.

What are the predictions for the market size in the coming years?

The uveitis treatment market is projected to witness significant expansion in the upcoming years, reaching a value of 2.08 billion by the year 2029, with a compound annual growth rate (CAGR) of 7.8%. The spike in the market during the forecast period can be connected to the ameliorated affordability of healthcare services, the escalating prevalence of age-related eye issues, a growing senior demographic, amplified research undertakings, and heightened public consciousness about eye health. Prime trends in the forecast period will encompass the evolution of targeted treatments, advancements in laser eye surgery, the introduction of innovative drug administration systems, progress in diagnostic tools related to ophthalmology, and a rise in the use of sustained-release drug delivery systems.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/uveitis-treatment-global-market-report

Which key drivers are propelling the market’s growth?

The surge in autoimmune conditions is anticipated to accelerate the expansion of the uveitis treatment market. Autoimmune conditions are a collection of diseases where the immune system attacks and damages the body’s healthy cells, tissues, or organs. The escalating incidence of these conditions is fueled by factors like genetic predisposition, environmental factors, and alterations in lifestyle and immune system activities. Uveitis treatments assist in controlling autoimmune diseases by reducing inflammation, curbing immune system hyperactivity, and preventing sight loss associated with inflammation of the eye related to autoimmune diseases. For example, as per Versorgungsatlas, a health data analytics company based in Germany, reported in November 2024, that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, leading to a raw prevalence rate of 8.61%. Hence, the escalating prevalence of autoimmune conditions is fueling the growth of the uveitis treatment market.

How is the global market divided into key segments?

The uveitis treatment market covered in this report is segmented –

1) By Indication: Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis

2) By Route Of Administration: Topical, Systemic, Injectable

3) By Cause: Infectious, Non-infectious

4) By Treatment: Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anterior Uveitis: Infectious Anterior Uveitis, Non-Infectious Anterior Uveitis

2) By Intermediate Uveitis: Infectious Intermediate Uveitis, Non-Infectious Intermediate Uveitis

3) By Posterior Uveitis: Infectious Posterior Uveitis, Non-Infectious Posterior Uveitis

4) By Panuveitis: Infectious Panuveitis, Non-Infectious Panuveitis

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21313&type=smp

Who are the key firms paving the way for growth in the market?

Major companies operating in the uveitis treatment market are Merck & Co. Inc., AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Kubota Vision Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Horizon Therapeutics plc, Cipla Ltd., Santen Pharmaceutical Co. Ltd., Galapagos NV, ANI Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc., Entod Pharmaceuticals Ltd., Sirion Therapeutics Inc., Kiora Pharmaceuticals Inc., Lux Biosciences Inc., Inflammasome Therapeutics Inc., Clearside Biomedical Inc.

What key trends are currently impacting the market’s development?

Leading businesses in the uveitis treatment market are turning their focus towards creating innovative solutions like sustained-release intravitreal implants to enhance patient compliance. These implants are advanced drug delivery devices placed within the eye for a controlled, extended period of medication delivery. For example, in February 2022, Alimera Sciences, an American biopharmaceutical enterprise, premiered ILUVIEN in Spain. ILUVIEN, a groundbreaking sustained-release intravitreal implant, is intended to address non-infectious posterior uveitis (NIPU). The implant efficiently delivers the medication fluocinolone acetonide directly to the eye, gradually releasing it over up to 36 months, thereby providing a lasting solution for inflammation reduction and recurrence prevention in recurrent NIPU. As the sole solution of its kind for this specific application, ILUVIEN aims to lessen injection frequency and enhance patient results through a more steady, enduring effect.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21313

What regions are contributing significantly to the growth of the market?

North America was the largest region in the uveitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uveitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Stem Cell/Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Blood Bank Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-bank-global-market-report

Blood Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: